EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 12
Issue: 1
Year: 2025

ZOLGENSMA (ONASEMNOGENE-ABEPARVOVEC) DRUG USED IN SPINAL MUSCULAR ATROPHY(SMA)

Vignesh S.[*1], Nandhitha P.[2], Jothimanivannan C.[3], Vinothini A.[1] and Aravinth M.[1]

[1]Student, SS Institute of Pharmacy, Sankari, Salem – 637301, India.
[2]Assitant Professors, SS Institute of Pharmacy, Sankari, Salem – 637301, India.
[3]Professor & Principal, SS Institute of Pharmacy, Sankari, Salem – 637301, India.

***Corresponding Author: Vignesh S.**
Student, SS Institute of Pharmacy, Sankari, Salem – 637301, India.

Article Received on 15/11/2024 **Article Revised on 04/12/2024** **Article Accepted on 25/12/2024**

ABSTRACT
ZOLGENSMA (ONASEMNOGENE ABEPARVOVEC) is a gene therapy used to treat spinal muscular atropy (SMA), a rare genetic disease caused by a problem with the SMN1 gene. This gene helps make a protein needed for muscle strength, and when it doesn't work, muscles strength, and when it doesn't work, muscles get weaker over time. Zolgensma works by using a virus (AAV9) to deliver a healthy copy of the SMN1 gene to the muscles, allowing them to produce the needed protein and stop the disease from getting worse. It ' s given as a single intravenous infusion and has shown great results, especially in babies with the most severe form of SMA (TYPE1).early treatment can help babies reach important motor milestones, like sitting, standing, and breathing without help. common side effects may include liver damage or low platelet counts. approved by the U.S FDA in 2019, zolgensma is a promising treatment that could significantly improve life for those with SMA, even though it is very expensive.

KEYWORDS: spinal muscular atrophy, zolgensma (onasemnogene abeparvovec), SM1GENE, adeno virus (AAV9).

INTRODUCTION

Zolgensma (onasemnogene abeparvovec-xioi) is an innovative gene therapy developed to treat spinal muscular atrophy (SMA), a rare and potentially fatal genetic disorder that affects muscle strength and movement. SMA is caused by a mutation or deletion in the SMN1 gene, leading to a deficiency of survival motor neuron (SMN) protein, which is critical for motor neuron function. Without adequate SMN protein, motor neurons deteriorate, causing progressive muscle weakness and, in severe cases, respiratory failure. Zolgensma is a one-time intravenous infusion that delivers a functional copy of the SMN1 gene to motor neuron cells using a viral vector. This enables the production of SMN protein, helping to preserve motor neuron function and slow disease progression. Approved for children under two years of age, Zolgensma is most effective when administered early, ideally before significant symptoms develop. Regarded as a breakthrough in gene therapy, Zolgensma addresses the root cause of SMA rather than just managing its symptoms. Clinical trials and real-world data have demonstrated improvements in motor function, developmental milestones, and survival rates in treated children. As one of the most advanced treatments for genetic disorders, Zolgensma offers hope for families affected by SMA and highlights the potential of gene therapy to transform rare diseasecare.

SPINAL MUSCULAR ATROPY

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that causes muscle weakness throughout the body due to malfunctioning nerve cells in the spinal cord and brainstem. It is the leading genetic cause of infant death.

There are four types of Spinal Muscular Atrophy (SMA).

- **Type 1** is the most severe and common form, often referred to as Werdnig-Hoffmann disease or infantile-onset SMA. Infants with Type 1 have significant muscle weakness, cannot sit unsupported, and struggle with breathing, swallowing, and feeding. Symptoms appear at birth or within the first six months, and many children with this form do not survive past the age of two.
- **Type 2** is considered an intermediate form of SMA. Children with Type 2 may gain the ability to sit without support but are unable to walk independently. Symptoms typically emerge between 6 to 18 months of age. Depending on the severity,

children with Type 2 can have a normal life expectancy.

- **Type 3**, also known as Kugelberg-Welander disease, is a milder version of SMA that resembles muscular dystrophy. While children with Type 3 are typically able to walk, many experience difficulty, and some may eventually need a wheelchair. Symptoms generally surface around 18 months or in early childhood. Children with this type usually have nearly normal life expectancy.
- **Type 4** is a rare form of SMA that typically appears in early adulthood. It is generally a mild form of the condition.



DIAGNOSIS

The clinical features strongly point toward a diagnosis of Spinal Muscular Atrophy (SMA), especially in its severe form, characterized by a floppy or weak infant. Cognitive function and attentiveness remain intact. The muscle weakness is typically symmetrical, more pronounced in the proximal muscles, particularly in the legs compared to the arms. The severity of weakness correlates with the age of onset, with delayed motor milestones based on clinical classification. Sensory function is generally unaffected, and deep tendon reflexes are either absent or diminished depending on the disease's onset and progression. In the most severe cases, additional symptoms include poor head control, weak cry and cough, difficulty swallowing and feeding, tongue atrophy and fasciculations, and reliance on diaphragmatic breathing (abdominal breathing). The initial diagnostic step for suspected SMA is to test for a homozygous deletion in the SMN1 gene. The absence of exon 7 of the SMN1 gene (with or without exon 8 deletion) confirms the diagnosis, offering up to 95% sensitivity and nearly 100% specificity. If the initial test is negative, additional tests, such as measuring creatine kinase levels and conducting electromyography (EMG) and nerve conduction studies, should be carried out. If EMG findings suggest motor neuron disease, further genetic testing for SMN mutations is recommended. Modern genetic testing methods, such as multiplex ligation-dependent probe amplification, provide quick and reliable SMN1 gene copy number analysis.[1]



TREATMENT OF THE SPINAL MUSCULAR ATROPY

- Zolgensma is the only drug used for the purpose of spinal muscular atropy. Primarily due to the excessive costs. Its needed for the gene theraphy. This condition it priced at indian rupee around 16 crores.
- Corticosteroid (prednisolone) therapy starts one day before the infusion and continues for 30 days because Corticosteroid therapy is used in conjunction with Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA), to manage and mitigate potential immune and inflammatory responses. Here's why corticosteroids are important in this context:

1. Immune Modulation

Zolgensma is delivered via an adeno-associated virus (AAV9) vector, which can trigger an immune response against the viral capsid. The immune system might attack the therapy, reducing its effectiveness. Corticosteroids suppress this immune response, helping the therapy work as intended.

2. Liver Function Protection

The liver metabolizes the AAV vector used in Zolgensma, which can lead to elevated liver enzymes (a sign of liver inflammation). Corticosteroids help protect the liver by reducing inflammation and preventing damage.

3. Minimizing Side Effects

Some children may experience serious side effects, such as acute liver injury, after receiving Zolgensma. Corticosteroids reduce the likelihood of such adverse events by controlling inflammation and maintaining stable liver function.

4. Dosing Protocol

Patients typically begin corticosteroid therapy (like prednisone or prednisolone) before receiving Zolgensma and continue for several weeks after treatment. The exact duration and dosage depend on liver enzyme monitoring and overall response to the therapy.

PRODUCT DETAILS OF ZOLGENESMA

Active ingredient (main ingredient)	Onasemnogene abeparvovec
Other ingredients (inactive ingredient)	Trometamol, Magnesium chloride, Hexahydrate, Sodium chloride, Poloxamer, Hydrochloric acid (for ph adjustment), Water for for injections

Zolgensma, a gene therapy used to treat spinal muscular atrophy (SMA), is among the most expensive medications in the world. As of recent updates.

- Price in the United States: Approximately $2.1 million for a single-dose treatment.

- Price in other countries: It varies depending on agreements with health systems and insurers. For example, some countries have negotiated lower costs, and payment plans are sometimes available.
- While the upfront cost is high, Zolgensma is designed as a one-time treatment, potentially reducing the need for lifelong treatments associated with SMA. Insurance coverage, government programs, and financial assistance initiatives may be available to help patients access the therapy.
- Novartis is working with several countries to prepare for Zolgensma, a gene therapy for spinal muscular atrophy (SMA), including Brazil, India, Turkey (Key expansion market for zolgensma)
- Novartis has also scaled back its global Managed Access Programme (gMAP) for Zolgensma to 12 countries. These countries include Colombia, India, Indonesia, Malaysia, Mexico, New Zealand, Philippines, Serbia, Singapore, and Thailand.

MECHANISM OF ACTION

1. Gene Delivery Using AAV9 Vector

Zolgensma uses an adeno-associated virus serotype 9 (AAV9) vector as a delivery system. AAV9 has the ability to cross the blood-brain barrier and efficiently deliver genetic material to motor neurons in the central nervous system (CNS). The AAV9 vector carries a functional copy of the SMN1 gene under the control of a ubiquitous promoter, ensuring that the gene is expressed in various tissues, including motor neurons.

2. Expression of SMN Protein

Once inside the target cells (primarily motor neurons), the functional SMN1 gene is transcribed and translated, leading to the production of the SMN protein. The SMN protein restores proper function and survival of motor neurons, preventing degeneration and promoting better motor function.

3. Sustained Effect

Zolgensma is designed as a one-time treatment, providing long-term therapeutic benefit by enabling the continuous production of SMN protein in treated cells.

KEY FEATURES

- **Targeted therapy:** Directly addresses the root cause of SMA by replacing the missing or mutated SMN1 gene.
- **Systemic delivery:** The AAV9 vector ensures widespread distribution, reaching motor neurons throughout the CNS and peripheral tissues.

By restoring SMN protein levels, Zolgensma halts the progression of SMA, improves motor function, and significantly enhances the quality of life for patients.



DOSAGE OF ZOLGENESMA

- Zolgensma is given through an IV infusion over 60 minutes.

Weight(Kg)	Total dose (Vector genomes)	Infusion volume (Ml)
2.0	2.2×10^{14}	11.0
2.5	2.2×10^{14}	13.75
3.0	2.75×10^{14}	16.5
3.5	3.3×10^{14}	19.25
4.0	3.85×10^{14}	22.0
4.5	4.4×10^{14}	24.75
5.0	4.95×10^{14}	27.5
5.5	5.5×10^{14}	30.25
6.0	6.05×10^{14}	33.0
6.5	6.6×10^{14}	35.75
7.0	7.15×10^{14}	38.5
7.5	8.25×10^{14}	41.25

Formula Used

Total Dose: 1.1 x 10^{14} vector genomes per kg of body weight.

Infusion Volume: 5.5 mL per kg of body weight.

PREPARATION OF ZOLGENSMA

1. Storage and Handling

Zolgensma is stored frozen at -60°C to -90°C. Thaw the vials at 2°C to 8°C (refrigerator) for approximately 16 hours or at room temperature for about 6 hours before administration. Once thawed, the vials should not be refrozen and must be used within 14 days if kept refrigerated.

2. Inspection

Visually inspect each vial for particulate matter or discoloration before use.

The solution should be clear to slightly opalescent and colorless to faintly yellow.

3. Calculation of Dose

The dose is determined based on the patient's weight: 1.1 × 10^{14} vector genomes (vg) per kilogram (kg) of body weight.

Use the provided prescribing information to calculate the total dose and the number of vials needed.

4. Preparation of Syringe

Using aseptic technique, withdraw the appropriate dose from the vial(s) into a syringe.

Discard any unused portion of the vial as Zolgensma does not contain preservatives.

Administration of Zolgensma

1. Pre-medication

Administer systemic corticosteroids (e.g., prednisolone) 24 hours before infusion to mitigate potential immune reactions.

Follow the recommended steroid regimen for at least 30 days post-infusion, with gradual tapering as guided by liver function tests.

2. Infusion

Administer Zolgensma as a single-dose intravenous (IV) infusion over 60 minutes using a syringe pump.

Use a sterile, low-protein-binding 0.2-micron inline filter during administration.

3. Post-administration Monitoring

monitor the patient for any infusion-related reactions during and after administration.

conduct regular liver function tests (alt, ast, and total bilirubin) for at least 3 months post-treatment to detect any liver enzyme elevations.

Special Considerations

Ensure that the facility is equipped for managing potential anaphylactic reactions.

Dispose of Zolgensma and associated materials following appropriate biohazard waste protocols.

Educate caregivers about potential side effects, including fever, vomiting, or liver complications, and when to seek medical attention.

For precise dosing and protocols, always refer to the official prescribing information provided by the manufacturer.

Clinical Efficacy of Zolgensma

Zolgensma's clinical efficacy in treating Spinal Muscular Atrophy (SMA) has been demonstrated through pivotal trials like the Phase III STR1VE and the START studies. These studies highlighted significant benefits compared to the natural progression of untreated SMA.

1. Motor Milestones: A significant proportion of treated infants achieved key developmental milestones, such as sitting unassisted—a milestone rarely reached by untreated SMA patients.

2. Survival: Treated infants exhibited markedly improved survival rates without requiring permanent ventilation, which is a critical outcome in severe SMA Type 1.

3. Durability: Long-term follow-up data show that the therapeutic effects of Zolgensma are sustained over time, with ongoing expression of the SMN protein, underscoring the treatment's potential for lasting benefit. These results establish Zolgensma as a transformative therapy for SMA, particularly in early treatment.

Safety Profile

Zolgensma is generally well-tolerated, though adverse events can occur. The most Common side effect is elevated liver enzymes, which is why corticosteroid regimens are typically used alongside the therapy to reduce the risk of hepatotoxicity. Other potential risks include thrombotic microangiopathy and immune responses to the AAV9 viral vector. As a result, close monitoring is essential both during and after treatment to ensure safety and address any complications promptly.

Comparisons with Other SMA Therapies

Unlike Zolgensma, other treatments for spinal muscular atrophy (SMA), such as Spinraza (nusinersen) and Evrysdi (risdiplam), focus on modulating SMN2 expression rather than directly addressing the SMN1 mutation. Spinraza and Evrysdi require ongoing administration, making Zolgensma's one-time gene therapy approach a major advantage. However, Zolgensma faces challenges, including a high upfront cost exceeding $2 million and eligibility restrictions based on age and weight, which can limit accessibility. Despite these hurdles, Zolgensma offers the potential for long-term benefits and reduced treatment burden compared to chronic therapies.

REPORTING OF SIDE EFFECTS

If you experience any side effects after taking a medication, it is essential to seek medical advice promptly. Your healthcare provider will be able to assess

your symptoms and offer guidance on the appropriate course of action. In addition to seeking medical help, it is important to report the side effects to the Therapeutic Goods Administration (TGA) for further review. The TGA plays a crucial role in monitoring the safety and effectiveness of medicines available in Australia, and your report can contribute valuable information to improve safety data for the medication. By reporting side effects, you help ensure that other individuals who may be using the same medicine are informed of potential risks. You can submit your report easily through the TGA website at www.tga.gov.au/reporting-problems. This process helps the TGA assess patterns of side effects and take necessary steps, such as updating warnings or reviewing the medicine's approval status. Reporting side effects is an important part of maintaining public health and ensuring that medications remain safe for use.

ADVERSE EFFECTS AND MANAGEMENT OF ZOLGENSMA

The most common and serious adverse effects of Zolgensma include

1. Liver Toxicity (Elevated Liver Enzymes)

- Zolgensma can cause elevated liver enzymes, which could lead to liver damage. Monitoring liver function before and after administration is essential.
- **Management:** If elevated liver enzymes are detected, patients may be treated with corticosteroids (e.g., dexamethasone) to reduce inflammation and prevent further damage. Regular liver function tests should be conducted, and dose adjustments or temporary interruption of the therapy may be needed.

2. Thrombocytopenia (Low Platelet Count)

- Zolgensma may cause a decrease in platelet count, which can increase the risk of bleeding.
- **Management:** Monitor platelet levels, and if necessary, platelet transfusions may be administered. In some cases, supportive care may be sufficient.

3. Immunogenic Reactions

- The immune system may mount a response against the therapy, which can lead to side effects.
- **Management:** Corticosteroids or other immune-modulating drugs may be used to manage inflammation or hypersensitivity reactions.

4. Respiratory Issues

- In some cases, patients might experience respiratory problems due to muscle weakness, especially in the early post-treatment period.
- **Management:** Supportive care, including respiratory therapy or mechanical ventilation, might be necessary, depending on the severity.

5. Neurological Effects

- There may be a risk of seizure-like activity, though this is rare.
- **Management:** Seizure precautions should be followed, and anticonvulsant medications may be used if seizures occur.

6. Infections

- Zolgensma is administered intravenously and may increase the risk of infections.
- **Management:** Standard infection control measures should be followed, and any signs of infection should be promptly treated.

7. Nausea and Vomiting

- Some children may experience gastrointestinal symptoms such as nausea and vomiting post-infusion.
- **Management:** Supportive care, including antiemetic medications, may help relieve symptoms.

Preventive Measures

- Pre-treatment screening for liver function, platelet count, and other relevant markers is essential.
- Corticosteroids are often prescribed proactively to minimize the risk of liver injury.
- Ensure careful monitoring of the patient after treatment to detect any potential complications early.

As with any new medication, adverse effects may vary by individual, and management should be tailored based on the patient's specific condition and response to treatment. Always follow the recommendations from the healthcare provider or treatment team.

STEROID PROTOCOLS AND MANAGEMENT OF ADVERSE EFFECTS IN ZOLGENSMA

This outline of steroid protocols and the management of adverse effects associated with Zolgensma is well-structured. To make it even more practical, here are some specific recommendations and details that can further help in real-world applications.

STEROID PROTOCOLS

Starting Steroids

Timing: Initiating corticosteroids at least 24 hours before Zolgensma infusion is critical to preemptively reduce the potential for immune response. Some centers may also recommend starting slightly earlier to allow time for the body to adjust to the steroids.

Alternate Dosing: In some cases, if the patient has a comorbidity or is at higher risk for side effects from steroids, a more gradual introduction might be considered, but this should always be aligned with a physician's guidance and based on the patient's specific health profile.

Duration of Steroid Use

- The 30-day minimum post-infusion is a general recommendation. However, it is important to tailor the duration and tapering plan to the individual's response to the
- treatment. Liver enzyme levels and any potential adverse effects observed during this time should guide further decision-making.

Tapering Schedule

- A slow reduction is critical to avoid rebound inflammation. Some clinics have customized tapering plans depending on specific needs, such as:Week 5-6
- adjustments: If liver enzymes remain abnormal after Week 4, you may extend the tapering phase, reducing the dose by increments of 0.25 mg/kg every 2 weeks.

Monitoring During Steroid Use

- **Liver Enzyme Monitoring**: Liver function tests are critical. A key practice is frequent testing during the first few weeks post-infusion, as liver toxicity is most commonly observed early.
- **Platelet Monitoring:** Regular platelet counts should also be done at least once a week to detect early signs of thrombocytopenia, even before clinical symptoms of bleeding appear.
- **Troponin-I:** While not always part of routine monitoring for other drugs, Zolgensma's potential cardiac effects necessitate checking troponin-I levels in certain cases, especially if there are signs of cardiac distress or elevated liver enzymes.

COST AND ACCESSIBILITY OF ZOLGENSMA

zolgensma (onasemnogene abeparvovec-xioi) is a groundbreaking gene therapy developed to treat spinal muscular atrophy (sma), a genetic disorder that leads to the loss of motor neurons and severe muscle weakness. this one-time gene therapy targets the root cause of sma by delivering a functional copy of the smn1 gene, which is crucial for producing the smn protein. the loss of smn protein leads to the progressive weakening of muscles in sma patients. zolgensma is particularly effective in treating younger children, ideally those under the age of two, as it can help prevent the onset of severe symptoms if administered early.

COST OF THE DRUG

- Zolgensma is one of the most expensive drugs globally, with a price tag of approximately $2.1 million for a single dose in the United States. This high cost reflects its nature as a one-time gene therapy, which aims to provide a lifelong solution to a life-threatening disease.
- While the list price is staggering, the actual cost can vary depending on the healthcare system, insurance coverage, and any negotiated discounts.
- Some programs offer financial assistance to help mitigate these costs for eligible patients. For instance, Novartis, the drug's manufacturer, provides support through their financial assistance programs, helping patients with insurance issues or high out-of-pocket expenses.

ACCESSIBILITY OF DRUG

- In the United States, Zolgensma is generally accessible to patients through private insurance, Medicaid, or other government programs, but the high price often creates a barrier. Many insurance companies have specific criteria for approval, such as age limits or disease severity, which can limit access. Financial assistance programs can also provide support to patients facing high out-of-pocket costs.
- Globally, the availability of Zolgensma varies. The drug is approved in the European Union, Canada, Japan, and several other countries, though access may still be restricted depending on the country's healthcare infrastructure and regulatory processes. In some regions, limited access to Zolgensma may exist due to its cost and healthcare system constraints, though other treatment options might be available.

Real-World Impact of Zolgensma

1. IMPROVED SURVIVAL RATES

One of the most profound impacts of Zolgensma has been on survival rates. Before its availability, SMA type 1 was fatal, with most children not surviving beyond infancy. Following treatment with Zolgensma, many children with SMA type 1 not only survive but live without requiring invasive respiratory support such as ventilators. This has dramatically changed the trajectory of the disease, allowing these children to thrive.

2. MOTOR FUNCTION IMPROVEMENT

Zolgensma has also led to significant improvements in motor functions for many patients, especially when administered early. Children who were unable to perform basic movements like sitting up, crawling, or even swallowing before receiving treatment have shown substantial recovery. Some have gone on to achieve milestones such as walking and feeding themselves, which would have been unimaginable in the past without therapeutic intervention. Early intervention, ideally before the child develops severe symptoms, has been shown to yield the best outcomes.

3. EARLY DIAGNOSIS AND INTERVENTION

The ability to diagnose SMA through genetic testing before the onset of symptoms has opened the door for early intervention, where Zolgensma is administered to infants who have not yet displayed significant signs of the disease. This pre-symptomatic treatment has been shown to be highly effective in preventing disease progression and preserving motor function. In fact, some children treated before symptoms appear have developed normally, avoiding most of the severe effects of SMA.

4. COST AND ACCESSIBILITY

While the results of Zolgensma are promising, one of the major challenges surrounding its use is its high cost. Priced at approximately $2 million per dose, it is one of the most expensive single-dose treatments in the world. The cost has raised concerns about insurance coverage, affordability, and access to the therapy, particularly in countries or regions with fewer resources. Although some healthcare systems have worked to provide coverage for the therapy, it remains a significant barrier for many families.

5. LONG-TERM EFFICACY AND SAFETY

Zolgensma has shown a generally favorable safety profile, with adverse effects typically being mild and temporary. However, as with any new treatment, the long-term efficacy and safety are still being closely monitored. While initial results are positive, ongoing studies aim to determine how well the therapy holds up over time and if there are any long-term side effects.

6. ETHICAL AND PSYCHOLOGICAL CONSIDERATIONS

the availability of zolgensma has also raised. ethical questions about the implications of genetic therapies. parents may face difficult decisions regarding when and how to treat their children, especially if the treatment is costly or if there are questions about its long-term effects. psychologically, families who see dramatic improvements in their children's health may experience a mixture of relief and pressure, given the high stakes involved.

FUTURE DIRECTIONS OF ZOLGENSMA

The future directions for Zolgensma include several potential developments and areas of focus

1. Expanded Indications: Zolgensma may be further evaluated for use in treating other genetic diseases involving motor neurons or similar pathophysiologies. Expanding its application beyond SMA could pave the way for broader use in neuromuscular and genetic disorders.

2. Improved Dosing Regimens: Current treatment with Zolgensma involves a single intravenous infusion, and research may explore the possibility of optimizing dosing strategies for better long-term efficacy or improving treatment outcomes in older patients who are not currently eligible for therapy.

3. Combination Therapies: Combining Zolgensma with other therapies, such as antisense oligonucleotides (like Spinraza) or other gene-editing technologies, may improve outcomes, particularly in patients with more severe forms of SMA or in those who are non-responders to current treatments.

4. Long-term Safety and Efficacy: More extensive follow-up studies are needed to assess the long-term safety and effectiveness of Zolgensma, especially given its high cost and the uncertainty about its lasting impact. These studies may influence future treatment guidelines and policies.

5. Broader Population Access: Zolgensma has a high price point, which may limit access in certain populations. Efforts to make the drug more affordable or accessible in low-income regions could improve its global reach.

6. Gene Therapy Advancements: The success of Zolgensma will likely drive advancements in gene therapy technologies, such as improved viral vectors, better gene delivery methods, and more precise gene-editing tools. This could lead to better outcomes and more efficient therapies for a wider range of genetic disorders.

7. Improved Patient Selection Criteria: Research will continue to refine which patients are best suited for treatment with Zolgensma, particularly focusing on age, disease severity, and genetic mutations. Identifying the optimal window for intervention could enhance the success rate of the therapy.

in summary, the future of zolgensma involves extending its impact on sma and other genetic disorders, optimizing its use, and improving its accessibility and affordability globally. the continued development of gene therapy as a field will also likely be influenced by the lessons learned from zolgensma's success.

The 2024 update to the European consensus on the use of Zolgensma

a gene therapy for spinal muscular atrophy (SMA), provides new insights based on clinical trial data and real-world experience. Key updates include:

1. Predictors of Treatment Response: SMA classification types (e.g., SMA type 1, 2, 3) do not reliably predict gene therapy outcomes. More important factors include the age at disease onset, disease duration, and motor function at treatment start. There is a need for more data on bulbar and respiratory functions.

2. Presymptomatic Patients: The number of SMN2 copies remains the best predictor for disease severity and the onset of symptoms. Treatment decisions should be based on this number, which must be measured by expert laboratories. Some babies detected through newborn screening may already have symptoms at birth.

3. Older and Heavier Patients: The effectiveness of Zolgensma for older and heavier patients (over 21 kg) is not well-documented. Caution is advised, as higher doses may carry additional risks. Alternative treatment options or spinal administration may be considered in such cases, although these are still under investigation.

4. Severely Affected Patients: For individuals with symptoms from birth, longer disease duration, or severe progression, the likely outcomes of gene therapy may be limited. Parents should be informed about potential disability despite therapy, and palliative care may also be considered.

5. Combination Treatments: There is no evidence to suggest that combining disease-modifying treatments improves outcomes. More clinical trials are needed to evaluate this.

6. Early Treatment: Starting gene therapy early, before symptoms appear, is critical to improving outcomes. Treatment should be initiated immediately for newly diagnosed patients, especially those identified via newborn screening.

7. Data Collection and Collaboration: Continuous data collection on the safety and efficacy of Zolgensma is essential, including systematic monitoring of patients over 21 kg. Collaboration between pharmaceutical companies, regulators, and patient representatives is crucial for ensuring transparency and improving treatment protocols.

These updated guidelines emphasize the importance of individualized treatment plans, particularly for patients in different stages of the disease and with varying disease severities.

CONCLUSION

- Zolgensma represents a groundbreaking advancement in the treatment of spinal muscular atrophy (SMA), offering hope to children diagnosed with this devastating genetic disorder. SMA, a rare neuromuscular condition that causes progressive muscle weakness and atrophy, was once considered a fatal diagnosis, particularly for those diagnosed in infancy or early childhood. Before the advent of treatments like Zolgensma, the prognosis for children with SMA was grim, with many not surviving past their second year of life. However, Zolgensma has revolutionized the treatment landscape, providing a life-changing option that targets the root cause of the disease.
- Zolgensma works by addressing the genetic mutation that causes SMA, specifically targeting the defective SMN1 gene. This gene is responsible for producing a protein essential for the survival of motor neurons, which control muscle movements. Without enough of this protein, motor neurons degenerate, leading to muscle weakness and loss of function. Zolgensma delivers a fully functional copy of the SMN1 gene to the patient's cells, effectively restoring the production of the crucial protein. This gene therapy approach offers the potential to halt or even reverse the progression of the disease, depending on the timing of treatment.
- The impact of Zolgensma on children with SMA has been nothing short of transformative. In clinical trials, children who received the therapy early in life demonstrated significant improvements in motor skills and overall development. Many children who might have been expected to experience severe disability or even death have gone on to lead more active and fulfilling lives. This success highlights the incredible potential of gene therapies in treating genetic disorders and offers a beacon of hope for families affected by SMA.
- As gene therapy continues to advance, the promise of treatments like Zolgensma extends beyond SMA. Researchers are optimistic that this to a larger population approach can be adapted to treat a wide range of other genetic diseases, opening up new possibilities for curing or managing previously untreatable conditions. However, challenges remain, including ensuring that these treatments are accessible to all who need them. The high cost of gene therapies like Zolgensma remains a barrier to widespread adoption, but the hope is that as the technology evolves and more therapies are developed, they will become more affordable and accessible.
- In conclusion, Zolgensma represents a major step forward in the fight against SMA, offering children with this debilitating condition a chance at a future full of possibilities. As gene therapy continues to evolve, there is hope that similar breakthroughs will pave the way for lasting solutions to other genetic diseases, bringing life-changing treatments to countless individualsaround the world.

REFERENCE

1. FDA (U.S. Food and Drug Administration) – Zolgensma Official information on Zolgensma's approval, indications, and safety. FDA Zolgensma Novartis (Manufacturer of Zolgensma) Details from the manufacturer, Novartis, about the treatment, its mechanism, and clinical trials. Zolgensma by Novartis.
2. FDA Approval and Treatment Overview: U.S. Food and Drug Administration. (2019). FDA approves first gene therapy for spinal muscular atrophy. U.S. FDA. Retrieved from https://www.fda.gov
3. https://smanewstoday.com/spinal-muscular-atrophy-diagnosis/
4. https://www.zolgensma.com
5. Cleveland Clinic https://my.clevelandclinic.org SMA (Spinal Muscular Atrophy): What It Is, Symptoms & Types.
6. Mendell, J. R., et al. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine, 377(18): 1713–1722. DOI: 10.1056/NEJMoa1706198
7. Al-Zaidy, S. A., et al. (2019). Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatric Pulmonology, 54(2): 179-185. DOI: 10.1002/ppul.24203
8. Novartis (2023). Zolgensma Prescribing Information.
9. www.tga.gov.au/reporting-problems. Your report helps improve safety information about the medicine.
10. Novartis (the manufacturer of Zolgensma): Their official website offers information about Zolgensma, including access programs and pricing details. https://www.novartis.com
11. The U.S. Food and Drug Administration (FDA): You can access regulatory approval information and the drug's official label on the FDA website. https://www.fda.gov

12. Spinal Muscular Atrophy Foundation: This non-profit organization offers resources on SMA, including treatment options like Zolgensma. https://www.smafoundation.org
13. PubMed and Medical Journals: For in-depth studies and publications on Zolgensma's effectiveness, cost, and accessibility, PubMed and other medical journals are valuable resources. https://pubmed.ncbi.nlm.nih.gov
14. Clinical Efficacy of Zolgensma: Chiriboga, C. A., et al. (2019). Single-Dose Gene Therapy for Spinal Muscular Atrophy. *New England Journal of Medicine*, 377(18): 1713-1722. DOI: 10.1056/nejmoa1909077
15. Zolgensma (Onasemnogene Abeparvovec): Novartis. (2020). Zolgensma® (onasemnogene abeparvovec) Overview. Novartis. Retrieved from https://www.novartis.com
16. Spinal Muscular Atrophy: National Institute of Neurological Disorders and Stroke. (2021). Spinal Muscular Atrophy Information Page. NIH. Retrieved from https://www.ninds.nih.gov
17. National Institute of Neurological Disorders and Stroke (NINDS) Information on spinal muscular atrophy and the available treatments, including Zolgensma. NINDS on Spinal Muscular Atrophy
18. Dubowitz, V.Chaos in the classification of SMA: a possible resolution Neuromuscul Disord, 1995; 5: 3-5 Full Text (PDF) PubMed Google Scholar
19. Wang, C.H. · Lunn, M.R. Spinal muscular atrophy: advances in research and consensus on care of patients Curr Treat Options Neurol, 2008; 10: 420-428. Crossref PubMed Google Scholar
20. Hamilton, G. · Gillingwater, T.H.Spinal muscular atrophy: going beyond the motor neuron Trends Mol Med., 2013; 19: 40-50. Full Text (PDF) PubMed Google Scholar Lefebvre, S. · Bürglen, L. · Reboullet, S.Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995; 80: 155-165. Abstract Full Text (PDF) PubMed Google Scholar
21. https://pharmaphorum.com/news/novartis-cleared-to-restart-trials-of-new-zolgensma-delivery-route
22. https://www.swissinfo.ch/eng/multinational-companies/novartis-unveils-positive-study-data-on-zolgensma-gene-therapy/73327552
23. https://www.novartis.com/news/media-releases/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset
24. "AAV9-mediated gene therapy for spinal muscular atrophy." *Molecular Therapy*, 2016. doi:10.1016/j.ymthe.2016.02.007.
25. https://www.drugs.com/dosage/zolgensma.html
26. https://www.medblog.ca/wp-content/uploads/2023/10/zolgensma.web(Figure 1)